Covid-19 Vaccines: Update on Production and Development in Germany
With the approval of the first coronavirus vaccines in the EU and other countries, the global pandemic response entered into a new phase.
With the approval of the first coronavirus vaccines in the EU and other countries, the global pandemic response entered into a new phase.
The EU’s regulatory authority has cleared the way for anti-Covid-19 inoculations to begin in Germany and other members of the European bloc.
The first Covid-19 vaccines have been approved in a number of countries – with approval in Europe also imminent. The next challenge will be distribution of the vaccine and rapid immunization.
Markets Germany
Gradian Diagnostics’ recent acquisition of Molzym is a fine example of international matchmaking, facilitated by Germany Trade & Invest.
German pharmaceutical company BioNTech and Pfizer have presented the first results of their phase 3 study to develop a Covid-19 vaccine that should provide more than 90 percent protection.
Markets Germany
The European Investment Bank (EIB) has signed a pair of financing agreements with German companies for the research, development and testing of medications to fight Covid-19 and other conditions.
There are currently 97 Covid-19 clinical studies registered in Germany, almost half of which are international studies - underlining Germany's leading role in global research for Covid-19 treatment.
Researchers in Germany play a leading role in the development of solutions to tackle the Coviod-19 pandemic. Especially the vaccine development projects are attracting attention.
Markets Germany
Telemedicine in Germany has made the leap from maybe-someday to must-have, and the sector continues to evolve at “corona crisis speed.”
Markets Germany
In the global race to deal with Covid-19, Germany’s extensive network of pharmaceutical companies are involved in major international collaborations and are benefiting from generous government support. German pharma is driving digitalization forward.